Survey about tolerance of the AS03-adjuvanted H1N1 influenza vaccine in children with rheumatic diseases.
Identifieur interne : 000166 ( Main/Exploration ); précédent : 000165; suivant : 000167Survey about tolerance of the AS03-adjuvanted H1N1 influenza vaccine in children with rheumatic diseases.
Auteurs : C. Sengler [Allemagne] ; M. Niewerth ; T. Kallinich ; A. Nimtz-Talaska ; M. Haller ; H-I Huppertz ; K. MindenSource :
- Clinical rheumatology [ 1434-9949 ] ; 2014.
Descripteurs français
- KwdFr :
- Adjuvants immunologiques (administration et posologie), Adolescent (MeSH), Allemagne (MeSH), Antirhumatismaux (usage thérapeutique), Arthrite juvénile (complications), Arthrite juvénile (traitement médicamenteux), Autoanticorps (composition chimique), Bases de données factuelles (MeSH), Enfant (MeSH), Enfant d'âge préscolaire (MeSH), Enquêtes et questionnaires (MeSH), Femelle (MeSH), Grippe humaine (immunologie), Grippe humaine (prévention et contrôle), Humains (MeSH), Mâle (MeSH), Méthotrexate (usage thérapeutique), Rhumatismes (complications), Rhumatismes (immunologie), Rhumatologie (normes), Sous-type H1N1 du virus de la grippe A (immunologie), Vaccination (MeSH), Vaccins antigrippaux (administration et posologie), État de santé (MeSH).
- MESH :
- administration et posologie : Adjuvants immunologiques, Vaccins antigrippaux.
- composition chimique : Arthrite juvénile, Autoanticorps, Rhumatismes.
- immunologie : Grippe humaine, Rhumatismes, Sous-type H1N1 du virus de la grippe A.
- normes : Rhumatologie.
- prévention et contrôle : Grippe humaine.
- traitement médicamenteux : Arthrite juvénile.
- usage thérapeutique : Antirhumatismaux, Méthotrexate.
- Adolescent, Allemagne, Bases de données factuelles, Enfant, Enfant d'âge préscolaire, Enquêtes et questionnaires, Femelle, Humains, Mâle, Vaccination, État de santé.
- Wicri :
- geographic : Allemagne.
English descriptors
- KwdEn :
- Adjuvants, Immunologic (administration & dosage), Adolescent (MeSH), Antirheumatic Agents (therapeutic use), Arthritis, Juvenile (complications), Arthritis, Juvenile (drug therapy), Autoantibodies (chemistry), Child (MeSH), Child, Preschool (MeSH), Databases, Factual (MeSH), Female (MeSH), Germany (MeSH), Health Status (MeSH), Humans (MeSH), Influenza A Virus, H1N1 Subtype (immunology), Influenza Vaccines (administration & dosage), Influenza, Human (immunology), Influenza, Human (prevention & control), Male (MeSH), Methotrexate (therapeutic use), Rheumatic Diseases (complications), Rheumatic Diseases (immunology), Rheumatology (standards), Surveys and Questionnaires (MeSH), Vaccination (MeSH).
- MESH :
- chemical , administration & dosage : Adjuvants, Immunologic, Influenza Vaccines.
- chemical , chemistry : Autoantibodies.
- chemical , therapeutic use : Antirheumatic Agents, Methotrexate.
- geographic : Germany.
- complications : Arthritis, Juvenile, Rheumatic Diseases.
- drug therapy : Arthritis, Juvenile.
- immunology : Influenza A Virus, H1N1 Subtype, Influenza, Human, Rheumatic Diseases.
- prevention & control : Influenza, Human.
- standards : Rheumatology.
- Adolescent, Child, Child, Preschool, Databases, Factual, Female, Health Status, Humans, Male, Surveys and Questionnaires, Vaccination.
Abstract
The objective of this study is to evaluate complications and changes in health status (disease activity and flare) in response to the AS03-adjuvanted H1N1 vaccine in children with rheumatic diseases. We conducted a nationwide survey addressing paediatric rheumatology sites who participated in the national paediatric rheumatology database. Ninety patients were documented-38 % under treatment with biologicals-of whom 18 % suffered from complications (10 % local and 8 % systemic) with no relevant changes in median disease activity or flare rate during 4 weeks following the vaccination. The adjuvanted H1N1 influenza vaccine seems to be adequately tolerated in children with rheumatic diseases.
DOI: 10.1007/s10067-013-2435-8
PubMed: 24288046
Affiliations:
Links toward previous steps (curation, corpus...)
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Survey about tolerance of the AS03-adjuvanted H1N1 influenza vaccine in children with rheumatic diseases.</title><author><name sortKey="Sengler, C" sort="Sengler, C" uniqKey="Sengler C" first="C" last="Sengler">C. Sengler</name><affiliation wicri:level="1"><nlm:affiliation>Epidemiology Unit, German Rheumatism Research Centre Berlin, Leibniz Institute, Charitéplatz 1, 10117, Berlin, Germany, sengler@drfz.de.</nlm:affiliation><country wicri:rule="url">Allemagne</country><wicri:regionArea>Epidemiology Unit, German Rheumatism Research Centre Berlin, Leibniz Institute, Charitéplatz 1, 10117, Berlin, Germany</wicri:regionArea><wicri:noRegion>Germany</wicri:noRegion><wicri:noRegion>Germany</wicri:noRegion><wicri:noRegion>Germany</wicri:noRegion></affiliation></author><author><name sortKey="Niewerth, M" sort="Niewerth, M" uniqKey="Niewerth M" first="M" last="Niewerth">M. Niewerth</name></author><author><name sortKey="Kallinich, T" sort="Kallinich, T" uniqKey="Kallinich T" first="T" last="Kallinich">T. Kallinich</name></author><author><name sortKey="Nimtz Talaska, A" sort="Nimtz Talaska, A" uniqKey="Nimtz Talaska A" first="A" last="Nimtz-Talaska">A. Nimtz-Talaska</name></author><author><name sortKey="Haller, M" sort="Haller, M" uniqKey="Haller M" first="M" last="Haller">M. Haller</name></author><author><name sortKey="Huppertz, H I" sort="Huppertz, H I" uniqKey="Huppertz H" first="H-I" last="Huppertz">H-I Huppertz</name></author><author><name sortKey="Minden, K" sort="Minden, K" uniqKey="Minden K" first="K" last="Minden">K. Minden</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2014">2014</date><idno type="RBID">pubmed:24288046</idno><idno type="pmid">24288046</idno><idno type="doi">10.1007/s10067-013-2435-8</idno><idno type="wicri:Area/Main/Corpus">000177</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">000177</idno><idno type="wicri:Area/Main/Curation">000177</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Curation">000177</idno><idno type="wicri:Area/Main/Exploration">000177</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Survey about tolerance of the AS03-adjuvanted H1N1 influenza vaccine in children with rheumatic diseases.</title><author><name sortKey="Sengler, C" sort="Sengler, C" uniqKey="Sengler C" first="C" last="Sengler">C. Sengler</name><affiliation wicri:level="1"><nlm:affiliation>Epidemiology Unit, German Rheumatism Research Centre Berlin, Leibniz Institute, Charitéplatz 1, 10117, Berlin, Germany, sengler@drfz.de.</nlm:affiliation><country wicri:rule="url">Allemagne</country><wicri:regionArea>Epidemiology Unit, German Rheumatism Research Centre Berlin, Leibniz Institute, Charitéplatz 1, 10117, Berlin, Germany</wicri:regionArea><wicri:noRegion>Germany</wicri:noRegion><wicri:noRegion>Germany</wicri:noRegion><wicri:noRegion>Germany</wicri:noRegion></affiliation></author><author><name sortKey="Niewerth, M" sort="Niewerth, M" uniqKey="Niewerth M" first="M" last="Niewerth">M. Niewerth</name></author><author><name sortKey="Kallinich, T" sort="Kallinich, T" uniqKey="Kallinich T" first="T" last="Kallinich">T. Kallinich</name></author><author><name sortKey="Nimtz Talaska, A" sort="Nimtz Talaska, A" uniqKey="Nimtz Talaska A" first="A" last="Nimtz-Talaska">A. Nimtz-Talaska</name></author><author><name sortKey="Haller, M" sort="Haller, M" uniqKey="Haller M" first="M" last="Haller">M. Haller</name></author><author><name sortKey="Huppertz, H I" sort="Huppertz, H I" uniqKey="Huppertz H" first="H-I" last="Huppertz">H-I Huppertz</name></author><author><name sortKey="Minden, K" sort="Minden, K" uniqKey="Minden K" first="K" last="Minden">K. Minden</name></author></analytic><series><title level="j">Clinical rheumatology</title><idno type="eISSN">1434-9949</idno><imprint><date when="2014" type="published">2014</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adjuvants, Immunologic (administration & dosage)</term><term>Adolescent (MeSH)</term><term>Antirheumatic Agents (therapeutic use)</term><term>Arthritis, Juvenile (complications)</term><term>Arthritis, Juvenile (drug therapy)</term><term>Autoantibodies (chemistry)</term><term>Child (MeSH)</term><term>Child, Preschool (MeSH)</term><term>Databases, Factual (MeSH)</term><term>Female (MeSH)</term><term>Germany (MeSH)</term><term>Health Status (MeSH)</term><term>Humans (MeSH)</term><term>Influenza A Virus, H1N1 Subtype (immunology)</term><term>Influenza Vaccines (administration & dosage)</term><term>Influenza, Human (immunology)</term><term>Influenza, Human (prevention & control)</term><term>Male (MeSH)</term><term>Methotrexate (therapeutic use)</term><term>Rheumatic Diseases (complications)</term><term>Rheumatic Diseases (immunology)</term><term>Rheumatology (standards)</term><term>Surveys and Questionnaires (MeSH)</term><term>Vaccination (MeSH)</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Adjuvants immunologiques (administration et posologie)</term><term>Adolescent (MeSH)</term><term>Allemagne (MeSH)</term><term>Antirhumatismaux (usage thérapeutique)</term><term>Arthrite juvénile (complications)</term><term>Arthrite juvénile (traitement médicamenteux)</term><term>Autoanticorps (composition chimique)</term><term>Bases de données factuelles (MeSH)</term><term>Enfant (MeSH)</term><term>Enfant d'âge préscolaire (MeSH)</term><term>Enquêtes et questionnaires (MeSH)</term><term>Femelle (MeSH)</term><term>Grippe humaine (immunologie)</term><term>Grippe humaine (prévention et contrôle)</term><term>Humains (MeSH)</term><term>Mâle (MeSH)</term><term>Méthotrexate (usage thérapeutique)</term><term>Rhumatismes (complications)</term><term>Rhumatismes (immunologie)</term><term>Rhumatologie (normes)</term><term>Sous-type H1N1 du virus de la grippe A (immunologie)</term><term>Vaccination (MeSH)</term><term>Vaccins antigrippaux (administration et posologie)</term><term>État de santé (MeSH)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Adjuvants, Immunologic</term><term>Influenza Vaccines</term></keywords><keywords scheme="MESH" type="chemical" qualifier="chemistry" xml:lang="en"><term>Autoantibodies</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Antirheumatic Agents</term><term>Methotrexate</term></keywords><keywords scheme="MESH" type="geographic" xml:lang="en"><term>Germany</term></keywords><keywords scheme="MESH" qualifier="administration et posologie" xml:lang="fr"><term>Adjuvants immunologiques</term><term>Vaccins antigrippaux</term></keywords><keywords scheme="MESH" qualifier="complications" xml:lang="en"><term>Arthritis, Juvenile</term><term>Rheumatic Diseases</term></keywords><keywords scheme="MESH" qualifier="composition chimique" xml:lang="fr"><term>Arthrite juvénile</term><term>Autoanticorps</term><term>Rhumatismes</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Arthritis, Juvenile</term></keywords><keywords scheme="MESH" qualifier="immunologie" xml:lang="fr"><term>Grippe humaine</term><term>Rhumatismes</term><term>Sous-type H1N1 du virus de la grippe A</term></keywords><keywords scheme="MESH" qualifier="immunology" xml:lang="en"><term>Influenza A Virus, H1N1 Subtype</term><term>Influenza, Human</term><term>Rheumatic Diseases</term></keywords><keywords scheme="MESH" qualifier="normes" xml:lang="fr"><term>Rhumatologie</term></keywords><keywords scheme="MESH" qualifier="prevention & control" xml:lang="en"><term>Influenza, Human</term></keywords><keywords scheme="MESH" qualifier="prévention et contrôle" xml:lang="fr"><term>Grippe humaine</term></keywords><keywords scheme="MESH" qualifier="standards" xml:lang="en"><term>Rheumatology</term></keywords><keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Arthrite juvénile</term></keywords><keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr"><term>Antirhumatismaux</term><term>Méthotrexate</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Adolescent</term><term>Child</term><term>Child, Preschool</term><term>Databases, Factual</term><term>Female</term><term>Health Status</term><term>Humans</term><term>Male</term><term>Surveys and Questionnaires</term><term>Vaccination</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Adolescent</term><term>Allemagne</term><term>Bases de données factuelles</term><term>Enfant</term><term>Enfant d'âge préscolaire</term><term>Enquêtes et questionnaires</term><term>Femelle</term><term>Humains</term><term>Mâle</term><term>Vaccination</term><term>État de santé</term></keywords><keywords scheme="Wicri" type="geographic" xml:lang="fr"><term>Allemagne</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">The objective of this study is to evaluate complications and changes in health status (disease activity and flare) in response to the AS03-adjuvanted H1N1 vaccine in children with rheumatic diseases. We conducted a nationwide survey addressing paediatric rheumatology sites who participated in the national paediatric rheumatology database. Ninety patients were documented-38 % under treatment with biologicals-of whom 18 % suffered from complications (10 % local and 8 % systemic) with no relevant changes in median disease activity or flare rate during 4 weeks following the vaccination. The adjuvanted H1N1 influenza vaccine seems to be adequately tolerated in children with rheumatic diseases. </div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">24288046</PMID><DateCompleted><Year>2014</Year><Month>09</Month><Day>29</Day></DateCompleted><DateRevised><Year>2018</Year><Month>11</Month><Day>13</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1434-9949</ISSN><JournalIssue CitedMedium="Internet"><Volume>33</Volume><Issue>1</Issue><PubDate><Year>2014</Year><Month>Jan</Month></PubDate></JournalIssue><Title>Clinical rheumatology</Title><ISOAbbreviation>Clin. Rheumatol.</ISOAbbreviation></Journal><ArticleTitle>Survey about tolerance of the AS03-adjuvanted H1N1 influenza vaccine in children with rheumatic diseases.</ArticleTitle><Pagination><MedlinePgn>137-9</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1007/s10067-013-2435-8</ELocationID><Abstract><AbstractText>The objective of this study is to evaluate complications and changes in health status (disease activity and flare) in response to the AS03-adjuvanted H1N1 vaccine in children with rheumatic diseases. We conducted a nationwide survey addressing paediatric rheumatology sites who participated in the national paediatric rheumatology database. Ninety patients were documented-38 % under treatment with biologicals-of whom 18 % suffered from complications (10 % local and 8 % systemic) with no relevant changes in median disease activity or flare rate during 4 weeks following the vaccination. The adjuvanted H1N1 influenza vaccine seems to be adequately tolerated in children with rheumatic diseases. </AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Sengler</LastName><ForeName>C</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Epidemiology Unit, German Rheumatism Research Centre Berlin, Leibniz Institute, Charitéplatz 1, 10117, Berlin, Germany, sengler@drfz.de.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Niewerth</LastName><ForeName>M</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Kallinich</LastName><ForeName>T</ForeName><Initials>T</Initials></Author><Author ValidYN="Y"><LastName>Nimtz-Talaska</LastName><ForeName>A</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Haller</LastName><ForeName>M</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Huppertz</LastName><ForeName>H-I</ForeName><Initials>HI</Initials></Author><Author ValidYN="Y"><LastName>Minden</LastName><ForeName>K</ForeName><Initials>K</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2013</Year><Month>11</Month><Day>28</Day></ArticleDate></Article><MedlineJournalInfo><Country>Germany</Country><MedlineTA>Clin Rheumatol</MedlineTA><NlmUniqueID>8211469</NlmUniqueID><ISSNLinking>0770-3198</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000276">Adjuvants, Immunologic</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018501">Antirheumatic Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D001323">Autoantibodies</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007252">Influenza Vaccines</NameOfSubstance></Chemical><Chemical><RegistryNumber>YL5FZ2Y5U1</RegistryNumber><NameOfSubstance UI="D008727">Methotrexate</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000276" MajorTopicYN="N">Adjuvants, Immunologic</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="Y">administration & dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018501" MajorTopicYN="N">Antirheumatic Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001171" MajorTopicYN="N">Arthritis, Juvenile</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001323" MajorTopicYN="N">Autoantibodies</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002648" MajorTopicYN="N">Child</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002675" MajorTopicYN="N">Child, Preschool</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016208" MajorTopicYN="N">Databases, Factual</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005858" MajorTopicYN="N" Type="Geographic">Germany</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006304" MajorTopicYN="N">Health Status</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D053118" MajorTopicYN="N">Influenza A Virus, H1N1 Subtype</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007252" MajorTopicYN="N">Influenza Vaccines</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="Y">administration & dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007251" MajorTopicYN="N">Influenza, Human</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000517" MajorTopicYN="Y">prevention & control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008727" MajorTopicYN="N">Methotrexate</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012216" MajorTopicYN="N">Rheumatic Diseases</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012219" MajorTopicYN="N">Rheumatology</DescriptorName><QualifierName UI="Q000592" MajorTopicYN="N">standards</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011795" MajorTopicYN="N">Surveys and Questionnaires</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014611" MajorTopicYN="N">Vaccination</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2013</Year><Month>05</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2013</Year><Month>11</Month><Day>03</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2013</Year><Month>11</Month><Day>30</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2013</Year><Month>11</Month><Day>30</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2014</Year><Month>9</Month><Day>30</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">24288046</ArticleId><ArticleId IdType="doi">10.1007/s10067-013-2435-8</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Ann Rheum Dis. 2007 Oct;66(10):1384-7</Citation><ArticleIdList><ArticleId IdType="pubmed">17284544</ArticleId></ArticleIdList></Reference><Reference><Citation>Arthritis Rheum. 2011 Jun;63(6):1486-96</Citation><ArticleIdList><ArticleId IdType="pubmed">21384334</ArticleId></ArticleIdList></Reference><Reference><Citation>Scand J Rheumatol. 2013;42(1):34-40</Citation><ArticleIdList><ArticleId IdType="pubmed">22992045</ArticleId></ArticleIdList></Reference><Reference><Citation>Clin Exp Rheumatol. 2001 Sep-Oct;19(5):589-94</Citation><ArticleIdList><ArticleId IdType="pubmed">11579723</ArticleId></ArticleIdList></Reference><Reference><Citation>Pediatr Infect Dis J. 2011 Mar;30(3):208-11</Citation><ArticleIdList><ArticleId IdType="pubmed">20861757</ArticleId></ArticleIdList></Reference><Reference><Citation>BMJ. 2010 May 27;340:c2649</Citation><ArticleIdList><ArticleId IdType="pubmed">20508026</ArticleId></ArticleIdList></Reference><Reference><Citation>Vaccine. 2010 Feb 17;28(7):1740-5</Citation><ArticleIdList><ArticleId IdType="pubmed">20034605</ArticleId></ArticleIdList></Reference><Reference><Citation>Ann Rheum Dis. 1974 May;33(3):248-54</Citation><ArticleIdList><ArticleId IdType="pubmed">4546350</ArticleId></ArticleIdList></Reference><Reference><Citation>Arthritis Rheum. 2007 Feb;56(2):639-46</Citation><ArticleIdList><ArticleId IdType="pubmed">17265499</ArticleId></ArticleIdList></Reference><Reference><Citation>J Rheumatol. 1993 Oct;20(10):1769-73</Citation><ArticleIdList><ArticleId IdType="pubmed">7848389</ArticleId></ArticleIdList></Reference><Reference><Citation>Vaccine. 2012 Jan 20;30(5):936-40</Citation><ArticleIdList><ArticleId IdType="pubmed">22138210</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></pubmed><affiliations><list><country><li>Allemagne</li></country></list><tree><noCountry><name sortKey="Haller, M" sort="Haller, M" uniqKey="Haller M" first="M" last="Haller">M. Haller</name><name sortKey="Huppertz, H I" sort="Huppertz, H I" uniqKey="Huppertz H" first="H-I" last="Huppertz">H-I Huppertz</name><name sortKey="Kallinich, T" sort="Kallinich, T" uniqKey="Kallinich T" first="T" last="Kallinich">T. Kallinich</name><name sortKey="Minden, K" sort="Minden, K" uniqKey="Minden K" first="K" last="Minden">K. Minden</name><name sortKey="Niewerth, M" sort="Niewerth, M" uniqKey="Niewerth M" first="M" last="Niewerth">M. Niewerth</name><name sortKey="Nimtz Talaska, A" sort="Nimtz Talaska, A" uniqKey="Nimtz Talaska A" first="A" last="Nimtz-Talaska">A. Nimtz-Talaska</name></noCountry><country name="Allemagne"><noRegion><name sortKey="Sengler, C" sort="Sengler, C" uniqKey="Sengler C" first="C" last="Sengler">C. Sengler</name></noRegion></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/GrippeAllemagneV4/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000166 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000166 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= GrippeAllemagneV4
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:24288046
|texte= Survey about tolerance of the AS03-adjuvanted H1N1 influenza vaccine in children with rheumatic diseases.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:24288046" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a GrippeAllemagneV4
| This area was generated with Dilib version V0.6.35. |  |